{"nctId":"NCT01639495","briefTitle":"THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS","startDateStruct":{"date":"2012-07-01","type":"ACTUAL"},"conditions":["Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation"],"count":148,"armGroups":[{"label":"THERMOCOOL® SMARTTOUCH™ Catheter","type":"EXPERIMENTAL","interventionNames":["Device: THERMOCOOL® SMARTTOUCH™ Catheter"]}],"interventions":[{"name":"THERMOCOOL® SMARTTOUCH™ Catheter","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have had at least 3 atrial fibrillation episodes within 6 months of this study\n* Have failed at least one antiarrhythmic drug shown by repeated atrial fibrillation episodes\n* 18 years of age or older\n\nExclusion Criteria including, but not limited to:\n\n* Have had previous ablation for atrial fibrillation\n* Have take amiodarone within 6 months of this study\n* Have had any heart surgery within the last 60 days\n* Have had a heart attack within the last 60 days\n* Females who are pregnant or breast feeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Achieved Freedom From Atrial Tachyarrhythmias","description":"Freedom from documented symptomatic atrial fibrillation/atrial tachycardia/atrial flutter (hereinafter collectively referred to as \"atrial tachyarrhythmias\") based on electrocardiographic data during the effectiveness evaluation period (Day 91-361). Acute procedure failures, antiarrhythmic drug(AAD) changes and repeat ablation occurring during evaluation period were deemed as primary effectiveness failures","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Peri-procedural Serious Adverse Events","description":"Peri-procedural serious adverse events (SAEs) are those non-primary SAEs occurred within 8-30 days post procedure","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Primary Adverse Events Within Specified Study Period","description":"Primary safety endpoint consists of primary adverse events (AE) within 7 days post procedure Or pulmonary vein stenosis and atrio-esophageal fistula events that occurred within 12 months post-procedure. Primary adverse events include death, myocardial infarction, pulmonary vein stenosis, diaphragmatic paralysis, atrio-esophageal fistula, transient ischemic attack, stroke / cerebrovascular accident, thromboembolism, pericarditis, cardiac tamponade, pericardial effusion, pneumothorax, atrial perforation, vascular access complications, pulmonary edema, initial and prolonged hospitalization (excluding those due to pre-existing arrhythmia recurrence), heart block.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieved Acute Effectiveness","description":"Acute effectivenesss is defined as confirmation of entrance block into all Pulmonary veins","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Late Onset Serious Adverse Events","description":"Late onset serious adverse events (SAEs) are those non-primary SAEs occurred after 31 days post procedure","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":46,"n":144},"commonTop":["Arrhythmia","Pericardial effusion","Haematoma","Atrial fibrillation","Chest pain"]}}}